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Background/Objective: Products of heme oxygenase 1 (HO1) possess antithrombotic properties, and impairment of HO1
activity may contribute to thrombus formation. Transcriptional activity of long GT-repeat alleles in HO1 gene
(HMOX1) is lower as compared with short alleles. We hypothesize that these long alleles are associated with decreased
HO1 anticoagulant activity and, thus, an increased risk of thrombosis..
Design/Methods: In a prospective cohort study, we followed 860 patients with a first VTE, and investigated the impact of
a promoter GT-dinucleotid length polymorphism in HOMX1 on the risk of recurrent venous thromboembolism (VTE).
Results: Allele groups short (S), medium (M) and long (L) of the promoter GT-dinucleotide length polymorphism were
distinguished. L-alleles, but not M- or S-alleles, were found to be more frequent among patients with recurrence.
Heterozygous carriers of L-alleles had a two-fold higher relative risk of recurrence [(RR 2.2 (95% CI: 1.4-3.4)] as
compared to wild type, which was independent of other thrombotic risk factors. At five years, the cumulative probability
of recurrence was 18% (95% CI: 15%-22%) in patients without an L-allele compared to 32% (95% CI: 19%-46%) in patients
heterozygous for the L-allele (P  .001).
Conclusion: Patients with first VTE and long GT-repeat alleles in HMOX1 have an increased risk of recurrence.
Genetically determined alterations in HO1 function may represent a new pathomechanism in VTE. ( J Vasc Surg 2008;
47:566-70.)Venous thromboembolism (VTE) is a chronic and mul-
ticausal disease.1 The annual incidence of recurrence ranges
between 5% to 10%, and approximately 5% of patients with
recurrence die from pulmonary embolism. The risk of VTE
depends upon the severity and number of risk factors in an
individual patient at a given point in time. Over the years,
numerous circumstantial and congenital risk factors of first
VTE have been identified. The relevance of these factors with
regard to stratifying patients according to their risk of recur-
rence is modest. Importantly, many patients with recurrent
VTE carry neither a clinical nor thrombophilic risk factor.
These findings suggest the existence of so far unknown risk
factors of recurrent VTE.
Experimental data indicate that products of heme oxy-
genase 1 (HO1) activity possess antithrombotic properties,
and impairment of HO1 activity may contribute to throm-
bus formation. HO1, the rate-limiting enzyme of heme
degradation, cleaves the heme ring at the alpha methene
bridge to form carbon monoxide (CO), ionic iron (Fe2),
and biliverdin, which is immediately converted to bilirubin
by biliverdin reductase. By conversion of pro-oxidant heme
into antioxidant bilirubin, HO1 acts as a major antioxi-
dant.2,3 Bilirubin, as well as systemic induction of HO1,
delays microvascular thrombus formation in vivo, probably
by a reduction of endothelial P-selectin.4 CO exerts anti-
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566coagulant effects by affecting fibrinolysis,5 platelet aggre-
gation,6-9 and by maintaining the integrity of the vessel
wall.10,11
The allele frequency of a polymorphic GT-repeat
(g.15167397GT (23_37); dbSNP rs3074372) in the pro-
moter of the HO1 gene (HMOX1) shows a trimodal
distribution with peaks at 23 repeats, 30 repeats, and above
33 repeats. Accordingly, alleles have been referred to as
short (S), medium (M), and long (L). Level of lipid peroxi-
dation in vivo and clinical conditions like restenosis after
percutaneous transluminal angioplasty as well as suscepti-
bility to coronary artery disease in diabetes are related to
HMOX1 genotype.12-15 Importantly, transcriptional activ-
ity as determined by luciferase reporter assays of long
GT-repeat alleles is lower compared with short alleles.12,16
We hypothesize that prevalence of long GT-repeat
alleles in HMOX1 leads to impaired HO1 anticoagulant
activity and is associated with increased risk of thrombosis.
In patients with venous thromboembolic disease, the role
of HMOX1 genotype has not been investigated so far. In a
large cohort study, we prospectively followed patients with
a first spontaneous VTE and evaluated the risk of recur-
rence in association with the polymorphic GT-repeat in the
promoter of the HMOX1 gene.
METHODS AND MATERIAL
Study population. Patients enrolled in the Austrian
Study on Recurrent Venous Thromboembolism (AUREC),
an ongoing, prospective, multicenter cohort study, were eli-
gible for the present analysis. The characteristics of the study
have been previously reported in detail.17 To fulfill the inclu-
sion criteria, patients had to be older than 18 years and had
to be treated with vitamin K-antagonists for at least 3
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to be objectified by venography or color duplex sonogra-
phy (in case of proximal deep vein thrombosis), and pul-
monary embolism had to be diagnosed by ventilation per-
fusion scan according to the criteria of the prospective
investigation of pulmonary embolism diagnosis or by
multi-slice computed tomography. Between July 1992 and
July 2004, 3006 patients with VTE were screened. Two
thousand and seventy-one (2071) patients were excluded
because of previous VTE, VTE secondary to surgery,
trauma, or pregnancy, deficiency of a natural coagulation
inhibitor, the lupus anticoagulant, cancer, and long-term
antithrombotic treatment for reasons other than VTE. In
75 patients (8%) of the remaining 935 patients, no valid
results of HMOX1 genotyping could be obtained.
Patients entered the study at the time of discontinua-
tion of vitamin K-antagonists, and were seen at 3-month
intervals during the first year and every 6 months thereafter.
All women were strongly discouraged from hormone re-
placement therapy or contraceptive pill use. Patients re-
ceived written information on the symptoms of VTE and
were instructed to report if symptoms occurred.
The study has been approved by the ethics committee
of the Medical University of Vienna and the patients had to
provide written informed consent prior to participation.
Data analyses were performed according to guidelines for
describing DNA polymorphism-disease associations.18
Study endpoint. The endpoint of the study was recur-
rent, symptomatic deep vein thrombosis confirmed by
venography or color duplex sonography (in case of proxi-
mal deep vein thrombosis of the contra lateral leg), or
symptomatic pulmonary embolism verified by perfusion
lung scan and/or multi-slice computed tomography.
Deep vein thrombosis was considered to have recurred
if the patient had a thrombus in the leg or arm not affected
by the previous thromboembolic event; a thrombus in
another deep vein in the leg or arm affected by the previous
event; or a thrombus in the same venous system affected in
the previous event, with proximal extension of the throm-
bus (if the upper limit of the original thrombus had been
visible) or with a constant-filling defect surrounded by
contrast medium (if the original thrombus had not been
visible). The diagnosis was established by an adjudication
committee consisting of independent clinicians and radiol-
ogists.
Blood sampling and laboratory analysis. Three
weeks after discontinuation of vitamin K-antagonists, ve-
nous blood was obtained after overnight-fasting. The
blood was placed in 1/10 volume of 0.11 mmol of triso-
dium citrate per liter, and centrifuged for 20 minutes at
2000 g. Plasma was stored at 80°C. Genomic DNA was
isolated from leukocytes using standard methods. Throm-
bophilic risk factors, including factor V Leiden, prothrom-
bin G20210A mutation, levels of factor VIII, antithrom-
bin, protein C, protein S, and the presence of a lupus
anticoagulant were determined, as previously reported.17
In case a natural inhibitor deficiency, a lupus anticoagulant,
homozygous, or double heterozygous mutations were de-tected at this time point, anticoagulant treatment was re-
sumed and the patients were excluded from the study.
Genotyping was performed by personnel blinded for
clinical data. For quality control genotyping was repeated
in random samples and matching results were obtained in
all cases (n  70). Nucleotide positions relate to HMOX1
reference sequences NT_011520 for genomic sequences.
Determination of the GT-Repeat located in the 5=-flanking
region of the HO1 gene (g.15167397GT (23_37); dbSNP
rs3074372) was done by polymerase chain reaction (PCR),
using a fluorescent-labeled sense primer and an unlabeled
antisense primer (5=-FAM-AGAGCCTGCAGCTTCT-
CAGA-3=; 5=-ACAAAGTCTGGCCATAGGAC-3=). PCR
products were generated in 25 l volumes containing 1.7
U of AmpliTaq Gold (Roche, Branchburg, NJ), 0.863
mmol/L MgCl2, 200 mol/L of each dNTP (Amersham
Pharmacia Biotech, Uppsala, Sweden), 4 pmol forward
primer, 4 pmol reverse primer, and approximately 4 ng
DNA. Amplifications were performed in 96-well plates
together with several water controls placed in between on
an Eppendorf Mastercycler (Eppendorf AG, Hamburg,
Germany). A 10-minute denaturation period at 95°C was
followed by 38 cycles of 93°C for 1 minute and 43°C for 5
minutes. A final extension step of 180 minutes at 72°
completed the reaction. The length of the PCR products
was determined relative to an internal size-standard (Ge-
neScan ROX 350 size standard, Applied Biosystems, Foster
City, Calif), after 5 minutes denaturation at 95° with a
tenfold volume of Hi-Di formamide (Applied Biosystems,
Foster City, Calif), on an automated DNA capillary se-
quencer (ABI Prism 3100 Genetic Analyser; Applied Bio-
systems, Foster City, Calif). Fragment length determina-
tion and GT-repeat length attribution was done semi
automatically using ABI Prism Software (Gene Scan Anal-
ysis Version 3.7 and Genotyper Software Version 3.7, both
Applied Biosystems, Foster City, Calif).
Statistical analysis. For numerical operations SPSS
software (SPSS Inc. Headquarters, Chicago, Ill) was used.
Values are given as means  SD. To test for homogeneity
between strata, we applied the log-rank and the generalized
Wilcoxon test. Categorical data were checked for homoge-
neity with the use of contingency-table analyses (by the 2
test if not indicated otherwise, or Fisher exact test). Simple
descriptive statistics were computed to provide a clear
presentation of data. For multivariate analyses, the data
were adjusted for potential confounding thrombotic vari-
ables, such as age, sex, factor V Leiden mutation, factor II
G20210A mutation, factor VIII, and body mass index
(weight in kilograms by the square of height in meters)
Times to recurrence (uncensored observations) or fol-
low-up times in patients without recurrence (censored ob-
servations) were analyzed according to survival methods.
The probability of recurrence was estimated according to
the method of Kaplan and Meier.19
RESULTS
Patients. Eight hundred and sixty (860) patients with
a first spontaneous VTE were included in the analysis. Of
hout
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study because of a diagnosis of cancer (16 patients), be-
cause of pregnancy (33 patients), or because of antithrom-
botic therapy for reasons other than VTE (149 patients); 18
(2.14%) patients were lost to follow-up; 13 patients died,
but in none recurrent VTE was the cause of death. Patients
were followed until the time of exclusion or death, when
data were censored.
VTE recurred in 134 (16%) of the 860 patients. Deep
vein thrombosis occurred in 84 patients and pulmonary
embolism in 50 patients; one of them was fatal. In 13
patients, recurrence was secondary to surgery (n  7) or
trauma (n  6). Compared with patients without recur-
rence, patients with recurrence were slightly older (47  16
years vs 50  14 years, P  .1) and had higher levels of
factor VIII (163  46 IU/dL vs 178  54 IU/dL P 
.017). Women were less frequent among recurrences (30%
vs 59%, P  .001). The proportion of carriers of factor V
Leiden (34% vs 28%) or factor II G20210A (10% vs 7%) did
not significantly differ between patients with and without
recurrence.
Length of GT-repeats in HMOX1 in patients with
VTE. Clustering the HMOX1 GT-repeat alleles into three
Table I. Distribution of 860 patients with and without re
SS S
No recurrence (n  726), no (%) 142 (20) 310
Recurrence (n  134), no (%) 23 (17) 51
All (n  860), no (%) 165 (19) 361
P  .049 (for trend).
Fig 1. GT-repeat alleles in patients with and without r
alleles in patients with recurrent (black columns) and witgroups, designated short (S; up to 29 repeats), medium (M;30 to 33 repeats), and long (L; from 34 repeats upward),
resulted in six genotype groups: SS, SM, SL, MM, ML, and
LL (Table I). Allele frequencies for S-alleles, M-alleles, and
L alleles were 44.9, 53.6, and 4.5%, respectively. The
overall distribution of genotypes was in agreement with the
Hardy Weinberg law (2 4.73; P [2df]   .05).
L-alleles and the risk of recurrent VTE. The fre-
quencies of GT-repeat alleles in patients with and without
recurrent are shown in Fig 1. Long GT-repeats of more
than 33 repeats were more frequent among patients with
recurrence than among those without recurrence (21 of
268[8%] vs. 56 of 1452[4%], P  .004). Also the six
genotypes were not evenly distributed in patients with and
without recurrence (Fisher exact test; P  .049; Table I).
As expected from allele frequencies, genotypes contain-
ing L alleles (genotypes SL and ML) were more frequent
among patients with recurrence, while other genotypes,
particularly SS, SM, and MM, showed a similar distribu-
tion in the two groups. When discriminating L-alleles
from other HMOX1-alleles, the frequency of homozy-
gous L/L genotypes, heterozygous L-allele genotypes,
and genotypes containing no L-allele was 0, 21, and 113
among 134 patients with recurrence, compared with 3,
nce according to GT-repeat genotype groups
SL MM ML LL
21 (3) 221 (30) 29 (4) 3 (0)
9 (7) 39 (29) 12 (9) 0 (0)
30 (4) 260 (30) 41 (5) 3 (0)
nt venous thromboembolism. Frequency of GT-repeat
recurrent VTE (grey columns).curre
M
(43)
(38)
(42)ecurre50, and 673 among 726 patients without recurrent VTE
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homozygous carriers of the L-allele (n  3) was too small
to perform adequate statistical analysis, these patients
were excluded from further analysis.
The characteristics of all patients with heterozygous
L-allele genotypes and of patients who did not carry an
L-allele are shown in Table II. Differences between the two
groups with regard to clinical and laboratory risk factors of
venous thrombosis were not seen. Carriers of an L-allele
had an increased risk of recurrent VTE. At 5 years, the
cumulative probability of recurrence was 18% (95% CI:
15%-22%) in patients without an L-allele compared with
32% (95% CI: 19%-46%) in patients with one L-allele
(log-rank test P  .001; Breslow test P  .02) (Fig 2). In
those patients the relative risk (RR) of recurrence was 2.2
([95% CI: 1.4 - 3.4]; P  .001) compared with non-carriers
of the L-allele. Adjustment for potential confounding vari-
ables including age, sex, prothrombin 20210A, factor V
Leiden, high factor VIII, and body mass index only slightly
Table II. Patient characteristics: heterozygous carriers of
no L-allele N
Female, no (%) 432 (55)
Age (y) 48 (36-6
Site of first VTE
Deep vein thrombosis, no (%) 450 (57)
Pulmonary embolism, no (%) 336 (43)
Observation time (mo) 39 (20-6
Duration of therapy (mo) 6.5 (5.9-7
Factor V Leiden; heterozygous 220 (28)
Factor II G20210A; heterozygous 59 (7,5)
Factor VIII level, IU/dL 161 (132-
Factor IX level, IU/dL 117 (101-
Recurrent VTE 113 (14)
Data are median (interquartile range) or number (percentage).
Fig 2. Kaplan Meier estimates of the risk of recurrent venous
thromboembolism for heterozygous carriers of an L-allele com-
pared with non-carriers.affected the RR (2.0 [95% CI:1.3-3.3]; P  .003).DISCUSSION
In 860 patients with a first spontaneous VTE, we
investigated the role of polymorphic HMOX1 genotypes
with regard to risk of recurrent VTE. HMOX1 promoter
GT-repeat alleles longer than 33 repeats were twice as
frequent among patients with recurrent VTE as among
those without recurrence. Important, relative risk of recur-
rence after a first thrombotic event was increased twofold
among patients carrying one long GT-repeat allele com-
pared with patients with short and medium length alleles.
This increased risk of recurrence was independent of other
confounding variables, including age, sex, and laboratory
thrombophilic risk factors. Only three patients were homozy-
gous carriers of the long GT-repeat allele, and none of these
patients had recurrent VTE. Although it is conceivable that
homozygous carriers of the L-allele are more prone to recur-
rent thrombosis than heterozygotes, we could not show this
effect most likely due to the small number of patients.
Genotypes containing only short or medium length
alleles were evenly distributed between patients with and
without recurrence. This is seemingly in contrast to find-
ings in patients after peripheral angioplasty in which the
presence of medium length alleles was associated with in
increased risk of early restenosis.15 This discrepancies, how-
ever, could be explained by patient selection or by different
functional features of HMOX1 alleles involved in the
pathomechanism of arterial and venous thrombotic disease.
Our study is the first to provide clinical evidence for a
potential role of HO1 activity in the pathogenesis of recur-
rent VTE in a large number of patients. The HMOX1
L-allele was independently associated with an increased risk
of recurrent VTE. There are some indications for a role of
HMOX1 polymorphisms in venous disease. Elevated oxi-
dative stress, measured in type 2 diabetic patients as level of
thiobarbituric acid reactive substances, was observed in
carriers of L-alleles.12 Increased oxidative stress is associ-
ated with platelet activation, which can contribute to
thrombus formation.20 Importantly, luciferase reporter as-
says indicate that the transcriptional activity of L-alleles is
lower compared with S-alleles.12,16 Lower HO1 activity
allele compared with non-carriers
6 heterozygous L-allele N  71 P
35 (49) .4
49 (38-62) .3
.03
29 (41)
42 (59)
33 (16-67) .4
6.4 (5.7-7.5) .9
27 (38) .1
7 (10) .5
173 (140-198) .2
121 (105-136) .2
21 (30) .001an L-
 78
0)
6)
.6)
195)
135)may result in impaired antithrombotic action of its metab-
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plasminogen activator inhibitor-1 in mononuclear phago-
cytes5 and inhibits platelet aggregation.6-8 CO also pre-
vents thrombus formation by maintaining the integrity of
the vessel wall through direct blocking of vascular cell
apoptosis as well as inhibiting release of pro-apoptotic
inflammatory cytokines from the vessel wall.10,11 Increased
apoptosis associated with the L-allele was reported in an in
vitro model of oxidant-induced apoptosis in lymphoblas-
toid cell lines.21 Experimental data indicate that bilirubin
delays microvascular thrombus formation in vivo by reduc-
ing levels of endothelial P-selectin.4 P-selectin is important
for fibrin formation and thrombus growth by supporting
platelet rolling, recruitment of platelets onto vascular injury
sites, and inducing generation of tissue-factor bearing micro-
particles.22 Interestingly, our cohort patients with recurrent
VTE had significantly higher levels of P-selectin than those
without recurrence. Patients with high P-selectin levels had an
almost twofold higher risk of recurrence compared with those
with lower levels.23
Due to the design of our study, we could not evaluate
whether HOMX1 polymorphisms are also a risk factor for a
first VTE. Thus, the role of this polymorphism in patients
with a first venous thrombotic event needs to be affirmed in
adequately designed studies. Furthermore, the effects of
the GT-length polymorphism, especially L-alleles, on HO1
activity need to be further elucidated by functional assays.
Our study in a large number of patients with a first VTE
provides novel aspects in the pathogenesis of recurrent
venous thrombotic disease. L-alleles of the promoter GT-
repeat length polymorphism in HMOX1 were more fre-
quent among patients with recurrent VTE compared with
those without recurrence. Long alleles were an independent
risk factor of recurrent VTE conferring a twofold increased
risk. Our study generated the hypothesis that genetically de-
termined alterations in HO1 function may represent a new
pathomechanism in venous thrombotic disease. Patients at
high risk of recurrent VTE could be identified by screening for
L-alleles of the promoter GT-repeat length polymorphism in
HMOX1 and thromboprophylactic treatment could be pro-
vided to these patients to avoid recurrent disease. Our find-
ings, however, need to be confirmed by other clinical studies
and in different patient populations.
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